Surgery Partners, Inc. (SGRY) Q1 2026 Earnings Call Transcript
Surgery Partners, Inc. (SGRY) Q1 2026 Earnings Call Transcript
SGRY - Surgery Partners, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.25
DETAILS
HIGH:
$21.00
LOW:
$17.00
MEDIAN:
$19.50
CONSENSUS:
$19.25
UPSIDE:
43.66%
Stock News
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
Surgery Partners (SGRY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago.
Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
BRENTWOOD, Tenn., May 05, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2026.
Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
BRENTWOOD, Tenn. , May 05, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ: SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights (All comparisons are year-over-year unless otherwise noted) Revenue increased 4.
AUNA vs. SGRY: Which Hospital Stock Looks More Attractive Now?
Auna S.A. gains from Peru growth, stabilizing Mexico and Colombia cash flow focus, while Surgery Partners faces earnings cuts and headwinds.
Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
BRENTWOOD, Tenn., April 17, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2026 results before the market opens on Tuesday, May 5, 2026, to be followed by a conference call at 8:30 a.m. (Eastern Time).
Reviewing Progyny (NASDAQ:PGNY) & Surgery Partners (NASDAQ:SGRY)
Progyny (NASDAQ: PGNY - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a summary of current
SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES
Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations NEW YORK, April 1, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the Company's GAAP financial results. Shareholders who suffered a loss are encouraged to submit their information here.
Surgery Partners (NASDAQ:SGRY) Reaches New 52-Week Low – What’s Next?
Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report)'s share price reached a new 52-week low during trading on Friday. The company traded as low as $11.53 and last traded at $11.6790, with a volume of 84480 shares traded. The stock had previously closed at $11.85. Analysts Set New Price Targets Several equities analysts have
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer 200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer
SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES
Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations NEW YORK, March 25, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the Company's GAAP financial results. Shareholders who suffered a loss are encouraged to submit their information here.
SGRY GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED -- LEVI & KORSINSKY, LLP INVESTIGATES
SURGERY PARTNERS (SGRY) GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED -- LEVI & KORSINSKY, LLP INVESTIGATES Levi & Korsinsky, LLP investigates whether Surgery Partners' forward guidance concealed known cost pressures and operational risks that later drove an earnings miss and guidance downgrade NEW YORK, March 18, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) shareholders watched the stock drop sharply in early March 2026 after Q4 2025 results and FY 2026 outlook both fell short of expectations. Months earlier, CEO Eric Evans told investors on the Q4 2024 earnings call: "we continue to expect margin expansion in 2025 and beyond.
8 Knots Management LLC Takes Position in Surgery Partners, Inc. $SGRY
8 Knots Management LLC acquired a new position in Surgery Partners, Inc. (NASDAQ: SGRY) during the undefined quarter, according to its most recent filing with the SEC. The fund acquired 220,088 shares of the company's stock, valued at approximately $4,763,000. Surgery Partners makes up about 0.5% of 8 Knots Management LLC's holdings, making
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director on its Board of Directors.
SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES
Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations NEW YORK, March 11, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the Company's GAAP financial results. Shareholders who suffered a loss are encouraged to submit their information here.
Surgery Partners, Inc. (SGRY) Presents at Barclays 28th Annual Global Healthcare Conference Prepared Remarks Transcript
Surgery Partners, Inc. (SGRY) Presents at Barclays 28th Annual Global Healthcare Conference Prepared Remarks Transcript
Ortelius Delivers Open Letter to Surgery Partners Stockholders
NEW YORK--(BUSINESS WIRE)--Ortelius Advisors, L.P. today issued the following open letter to stockholders of Surgery Partners, Inc. (NASDAQ: SGRY). March 10, 2026 Fellow Stockholders, Ortelius Advisors, L.P. (“Ortelius” or “we”) believes that Surgery Partners, Inc. (“Surgery” or the “Company”) has significant upside potential, based on its high-quality assets, favorable industry dynamics, and considerable free cash flow capabilities. However, we are deeply concerned by the Company's abysmal per.
Fraud Investigation Opened: Levi & Korsinsky Investigates Surgery Partners, Inc. (SGRY) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - March 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Surgery Partners, Inc. ("Surgery Partners, Inc.") (NASDAQ: SGRY) concerning potential violations of the federal securities laws. On March 3, 2025, CEO Eric Evans told investors on the Q4 2024 earnings call: "We expect margin expansion in 2025 and beyond.
Surgery Partners, Inc. to Present at Upcoming Investor Conference
BRENTWOOD, Tenn., March 09, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), is scheduled to meet with investors at the Barclays 28th Annual Global Healthcare Conference, including a presentation on Tuesday, March 10, 2026, at 2:30 p.m. (Eastern Time).
Surgery Partners, Inc. (NASDAQ:SGRY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report) has received an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company.
Price Targets
Surgery Partners price target raised to $17 from $15 at Jefferies
$17.00
(was $14.83)
Jefferies
Surgery Partners price target lowered to $15 from $16.25 at Jefferies
$15.00
(was $14.27)
Jefferies
UBS Reiterates Buy Rating on Surgery Partners (SGRY) Following Activist Letter to Shareholders
$21.00
(was $13.50)
US Capital Advisors
Surgery Partners (SGRY) PT Lowered to $16.25 at Jefferies
$16.25
(was $14.27)
Brian Tanquilut
·
Jefferies
Surgery Partners (SGRY) PT Lowered at RBC Capital as 2026 Guide Prompts Selloff
$20.00
(was $14.21)
Ben Hendrix
·
RBC Capital
Benchmark Reiterates Buy Rating on Surgery Partners (SGRY) Following Q4 Results
$30.00
(was $13.41)
Jefferies
Surgery Partners price target lowered to $19 from $22 at Mizuho
$19.00
(was $15.80)
Mizuho Securities
Surgery Partners price target lowered to $18 from $24 at Barclays
$18.00
(was $15.30)
Barclays
Surgery Partners price target lowered to $22 from $28 at Mizuho
$22.00
(was $15.20)
Mizuho Securities
Surgery Partners (SGRY) PT Lowered to $40 at Jefferies
$40.00
(was $29.74)
Brian Tanquilut
·
Jefferies
Surgery Partners (SGRY) PT Lowered to $31 at Barclays
$31.00
(was $29.74)
Andrew Mok
·
Barclays
UBS Starts Surgery Partners (SGRY) at Buy
$38.00
(was $30.46)
AJ Rice
·
UBS
Macquarie Starts Surgery Partners (SGRY) at Outperform
$31.00
(was $24.32)
Tao Qiu
·
Macquarie
Citigroup Maintains Buy on Surgery Partners, Raises Price Target to $64
$64.00
(was $53.62)
Citigroup